First results of CAR-PRISM: early safety and efficacy of CAR-T in high-risk smoldering myeloma
Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the early safety and efficacy of CAR T-cell therapy in precursor myeloma, highlighting the promising results of the CAR-PRISM (NCT05767359) study investigating ciltacabtagene autoleucel (cilta-cel) in high-risk smoldering multiple myeloma (HR-SMM). Dr Nadeem notes that the first six patients treated as part of the safety run-in experienced no dose-limiting toxicities, and all achieved a complete response with sustained measurable residual disease (MRD) negativity at 10^-6. None of the patients progressed to overt myeloma, suggesting that CAR T-cell therapy may offer a one-time treatment option to prevent disease progression in this high-risk patient population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
